Teligent Net Acquisitions/Divestitures 2010-2021 | TLGT

Teligent net acquisitions/divestitures from 2010 to 2021. Net acquisitions/divestitures can be defined as the total change in cash resulting from both investments in businesses and sales of businesses or business segments.
Teligent Annual Net Acquisitions/Divestitures
(Millions of US $)
2020 $N/A
2019 $N/A
2018 $N/A
2017 $N/A
2016 $N/A
2015 $N/A
2014 $N/A
2013 $N/A
2012 $N/A
2011 $N/A
2010 $N/A
2009 $N/A
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.000B $0.000B
Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.010B 6.96
Dr Reddy's Laboratories (RDY) India $11.261B 21.48
BridgeBio Pharma (BBIO) United States $6.894B 0.00
Bausch Health Cos (BHC) Canada $2.638B 1.91
Supernus Pharmaceuticals (SUPN) United States $1.805B 24.57
Amphastar Pharmaceuticals (AMPH) United States $1.553B 9.33
Taysha Gene Therapies (TSHA) United States $0.338B 23.57
Personalis (PSNL) United States $0.323B 0.00
Assembly Biosciences (ASMB) United States $0.080B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00